Gene
ZNF134
| Entrez Gene ID | 7693 (See on NCBI) |
| Description | zinc finger protein 134 |
| Gene Synonyms | pHZ-15 |
| Node consisting of this Gene | ZNF134 ZNF211///ZNF134 |
Networks including this gene
| GSE14095_top8000 - GSE14095 - SiGN-BN NNSR | Gene expression signature and the prediction of liver metastasis in colorectal cancer by DNA microarray |
| GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE10843_top8000 - GSE10843 - SiGN-BN NNSR | mRNA Cancer Cell Line Profiles |
| GSE10890_top8000 - GSE10890 - SiGN-BN NNSR | mRNA Breast Cancer Cell Line Profiles |
| GSE10972_top8000 - GSE10972 - SiGN-BN NNSR | Colon cancer |
| GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE12428_top8000 - GSE12428 - SiGN-BN NNSR | Current smoking-specific gene expression signature in bronchial epithelium is enhanced in squamous cell lung cancer |
| GSE12470_top8000 - GSE12470 - SiGN-BN NNSR | Gene expression profiles of serous ovarian cancer samples |
| GSE12472_top8000 - GSE12472 - SiGN-BN NNSR | A COPD-related gene expression signature in squamous cell lung cancer |
| GSE12777_top8000 - GSE12777 - SiGN-BN NNSR | Gene expression profiling of 51 human breast cancer cell lines |
| GSE12945_top8000 - GSE12945 - SiGN-BN NNSR | Expression data from colorectal cancers |
| GSE13067_top8000 - GSE13067 - SiGN-BN NNSR | Expression data from primary colorectal cancers |
| GSE13168_top8000 - GSE13168 - SiGN-BN NNSR | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13591_top8000 - GSE13591 - SiGN-BN NNSR | Integrated genomics approach to detect allelic imbalances in multiple myeloma |
| GSE13598_top8000 - GSE13598 - SiGN-BN NNSR | mRNA expression of 131 cancer cell lines |
| GSE13601_top8000 - GSE13601 - SiGN-BN NNSR | Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators |
| GSE13996_top8000 - GSE13996 - SiGN-BN NNSR | Molecular profiling of classical Hodgkin’s lymphoma tissues |
| GSE14206_top8000 - GSE14206 - SiGN-BN NNSR | Analysis of ETS gene expression patterns uncovers novel ETS mediated gene silencing pathways in prostate cancers |
| GSE14208_top8000 - GSE14208 - SiGN-BN NNSR | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top8000 - GSE14210 - SiGN-BN NNSR | Expression data from human endoscopic biopsy samples |
| GSE14786_top8000 - GSE14786 - SiGN-BN NNSR | Gene expression analysis of cancer-related fatigue in whole blood from breast cancer survivors |
| GSE15212_top8000 - GSE15212 - SiGN-BN NNSR | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
| GSE15329_top8000 - GSE15329 - SiGN-BN NNSR | Gene expression profiling of human non-Hodgkins lymphoma (NHL) cell lines |
| GSE15966_top8000 - GSE15966 - SiGN-BN NNSR | Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST) |
| GSE16120_top8000 - GSE16120 - SiGN-BN NNSR | Gene profiling, mutations and expression of epidermal growth factor receptor in androgen-dependent prostate cancer |
| GSE17536_top8000 - GSE17536 - SiGN-BN NNSR | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (Moffitt Samples) |
| GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
| GSE17764_top8000 - GSE17764 - SiGN-BN NNSR | Expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients |
| GSE18497_top8000 - GSE18497 - SiGN-BN NNSR | Diagnosis-relapse in ALL |
| GSE19494_top8000 - GSE19494 - SiGN-BN NNSR | Subcutaneous adipose tissue (SAT) gene expression patterns between weight control and regaining weight subjects |
| GSE20181_top8000 - GSE20181 - SiGN-BN NNSR | Letrozole (Femara) early and late responses to treatment |
| GSE20194_top8000 - GSE20194 - SiGN-BN NNSR | MAQC-II Project: human breast cancer (BR) data set |
| GSE2034_top8000 - GSE2034 - SiGN-BN NNSR | Breast cancer relapse free survival |
| GSE20842_top8000 - GSE20842 - SiGN-BN NNSR | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE22093_top8000 - GSE22093 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23036_top8000 - GSE23036 - SiGN-BN NNSR | Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma |
| GSE23177_top8000 - GSE23177 - SiGN-BN NNSR | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23553_top8000 - GSE23553 - SiGN-BN NNSR | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23772_top8000 - GSE23772 - SiGN-BN NNSR | Why does HAMLET preferentially kill tumor cells? p38-dependent death in tumor but up-regulation of innate immunity in healthy, differentiated cells |
| GSE23806_top8000 - GSE23806 - SiGN-BN NNSR | Expression data of glioblastoma stem-like (GS) cell lines, conventional glioma cell lines and primary tumors |
| GSE23988_top8000 - GSE23988 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE23991_top8000 - GSE23991 - SiGN-BN NNSR | Effect of zebularine on primary human liver cancer cell lines |
| GSE24124_top8000 - GSE24124 - SiGN-BN NNSR | Major gene partners of a favorable biomarker in ER(+) breast cancer |
| GSE25055_top8000 - GSE25055 - SiGN-BN NNSR | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top8000 - GSE25065 - SiGN-BN NNSR | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top8000 - GSE25066 - SiGN-BN NNSR | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26549_top8000 - GSE26549 - SiGN-BN NNSR | Gene Expression Profiling Predicts the Development of Oral Cancer |
| GSE26599_top8000 - GSE26599 - SiGN-BN NNSR | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE26906_top8000 - GSE26906 - SiGN-BN NNSR | APC colon stage II |
| GSE27480_top8000 - GSE27480 - SiGN-BN NNSR | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE2912_top8000 - GSE2912 - SiGN-BN NNSR | Molecular classification of multiple myeloma |
| GSE29288_top8000 - GSE29288 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Agilent WG platform) |
| GSE29817_top8000 - GSE29817 - SiGN-BN NNSR | Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor (EGFR) Predicts Outcome after Chemoradiotherapy of Lymph Node Negative Cervical Cancer |
| GSE30375_top8000 - GSE30375 - SiGN-BN NNSR | Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples |
| GSE31279_top8000 - GSE31279 - SiGN-BN NNSR | Decoding differentially regulated epithelial and stromal pathways in colorectal cancer |
| GSE3143_top8000 - GSE3143 - SiGN-BN NNSR | Breast Cancer Dataset |
| GSE31552_top8000 - GSE31552 - SiGN-BN NNSR | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE32474_top8000 - GSE32474 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Affymetrix U133 Plus 2.0) |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4122_top8000 - GSE4122 - SiGN-BN NNSR | Gene Expression Analysis of Ovarian Samples |
| GSE4459_top8000 - GSE4459 - SiGN-BN NNSR | Gene expression signature and the prediction of lymph node metastases |
| GSE4573_top8000 - GSE4573 - SiGN-BN NNSR | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE5206_top8000 - GSE5206 - SiGN-BN NNSR | Large-scale deployment of embryonic gene programming in human and murine colon cancer: a new target for intervention. |
| GSE5327_top8000 - GSE5327 - SiGN-BN NNSR | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5364_top8000 - GSE5364 - SiGN-BN NNSR | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE6008_top8000 - GSE6008 - SiGN-BN NNSR | Human ovarian tumors and normal ovaries |
| GSE6365_top8000 - GSE6365 - SiGN-BN NNSR | Distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| GSE6401_top8000 - GSE6401 - SiGN-BN NNSR | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6477_top8000 - GSE6477 - SiGN-BN NNSR | Expression data from different stages of plasma cell neoplasm |
| GSE7208_top8000 - GSE7208 - SiGN-BN NNSR | Expression data from 59 human colon tumor tissue samples |
| GSE7670_top8000 - GSE7670 - SiGN-BN NNSR | Expression data from Lung cancer |
| GSE8057_top8000 - GSE8057 - SiGN-BN NNSR | Expression data from ovarian cancer cells with time-course and concentration-profiles |
| GSE8332_top8000 - GSE8332 - SiGN-BN NNSR | Death receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL |
| GSE8401_top8000 - GSE8401 - SiGN-BN NNSR | Gene Signature for Aggression of Melanoma Metastases - Melanoma Metastasis |
| GSE8481_top8000 - GSE8481 - SiGN-BN NNSR | Various human cell types |
| GSE8546_top8000 - GSE8546 - SiGN-BN NNSR | Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure |
| GSE8835_top8000 - GSE8835 - SiGN-BN NNSR | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE9309_top8000 - GSE9309 - SiGN-BN NNSR | Recovery of biological information under heterogeneous experimental conditions using subgroup standardization. |
| GSE9348_top8000 - GSE9348 - SiGN-BN NNSR | Expression data from healthy controls and early stage CRC patient's tumor |
| GSE9750_top8000 - GSE9750 - SiGN-BN NNSR | Identification of gene expression profiles in cervical cancer |
| GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
| GSE9992_top8000 - GSE9992 - SiGN-BN NNSR | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
| GSE10810_top500tf - GSE10810 - SiGN-BN HC+Bootstrap | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE10843_top500tf - GSE10843 - SiGN-BN HC+Bootstrap | mRNA Cancer Cell Line Profiles |
| GSE10890_top500tf - GSE10890 - SiGN-BN HC+Bootstrap | mRNA Breast Cancer Cell Line Profiles |
| GSE10972_top500tf - GSE10972 - SiGN-BN HC+Bootstrap | Colon cancer |
| GSE11582_top500tf - GSE11582 - SiGN-BN HC+Bootstrap | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE11729_top500tf - GSE11729 - SiGN-BN HC+Bootstrap | H1299 EGF and Iressa stimulation |
| GSE12428_top500tf - GSE12428 - SiGN-BN HC+Bootstrap | Current smoking-specific gene expression signature in bronchial epithelium is enhanced in squamous cell lung cancer |
| GSE12470_top500tf - GSE12470 - SiGN-BN HC+Bootstrap | Gene expression profiles of serous ovarian cancer samples |
| GSE12472_top500tf - GSE12472 - SiGN-BN HC+Bootstrap | A COPD-related gene expression signature in squamous cell lung cancer |
| GSE12777_top500tf - GSE12777 - SiGN-BN HC+Bootstrap | Gene expression profiling of 51 human breast cancer cell lines |
| GSE12945_top500tf - GSE12945 - SiGN-BN HC+Bootstrap | Expression data from colorectal cancers |
| GSE13067_top500tf - GSE13067 - SiGN-BN HC+Bootstrap | Expression data from primary colorectal cancers |
| GSE13168_top500tf - GSE13168 - SiGN-BN HC+Bootstrap | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13255_top500tf - GSE13255 - SiGN-BN HC+Bootstrap | Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with NonSmall Cell Lung Cancer. |
| GSE13294_top500tf - GSE13294 - SiGN-BN HC+Bootstrap | Expression data from primary colorectal cancers |
| GSE13591_top500tf - GSE13591 - SiGN-BN HC+Bootstrap | Integrated genomics approach to detect allelic imbalances in multiple myeloma |
| GSE13598_top500tf - GSE13598 - SiGN-BN HC+Bootstrap | mRNA expression of 131 cancer cell lines |
| GSE13601_top500tf - GSE13601 - SiGN-BN HC+Bootstrap | Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators |
| GSE13861_top500tf - GSE13861 - SiGN-BN HC+Bootstrap | Gene expression signature-based novel prognostic risk score in gastric cancer |
| GSE13898_top500tf - GSE13898 - SiGN-BN HC+Bootstrap | Robust prognostic biomarkers for EAC identified by systems-level characterization of tumor transcriptome |
| GSE13911_top500tf - GSE13911 - SiGN-BN HC+Bootstrap | Expression data from primary gastric tumors (MSI and MSS) and adjacent normal samples |
| GSE13996_top500tf - GSE13996 - SiGN-BN HC+Bootstrap | Molecular profiling of classical Hodgkin’s lymphoma tissues |
| GSE14095_top500tf - GSE14095 - SiGN-BN HC+Bootstrap | Gene expression signature and the prediction of liver metastasis in colorectal cancer by DNA microarray |
| GSE14206_top500tf - GSE14206 - SiGN-BN HC+Bootstrap | Analysis of ETS gene expression patterns uncovers novel ETS mediated gene silencing pathways in prostate cancers |
| GSE14208_top500tf - GSE14208 - SiGN-BN HC+Bootstrap | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top500tf - GSE14210 - SiGN-BN HC+Bootstrap | Expression data from human endoscopic biopsy samples |
| GSE14333_top500tf - GSE14333 - SiGN-BN HC+Bootstrap | Expression data from 290 primary colorectal cancers |
| GSE14786_top500tf - GSE14786 - SiGN-BN HC+Bootstrap | Gene expression analysis of cancer-related fatigue in whole blood from breast cancer survivors |
| GSE15212_top500tf - GSE15212 - SiGN-BN HC+Bootstrap | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
| GSE15329_top500tf - GSE15329 - SiGN-BN HC+Bootstrap | Gene expression profiling of human non-Hodgkins lymphoma (NHL) cell lines |
| GSE15966_top500tf - GSE15966 - SiGN-BN HC+Bootstrap | Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST) |
| GSE16120_top500tf - GSE16120 - SiGN-BN HC+Bootstrap | Gene profiling, mutations and expression of epidermal growth factor receptor in androgen-dependent prostate cancer |
| GSE16391_top500tf - GSE16391 - SiGN-BN HC+Bootstrap | GGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial |
| GSE16581_top500tf - GSE16581 - SiGN-BN HC+Bootstrap | Genomic landscape of meningiomas: gene expression |
| GSE16757_top500tf - GSE16757 - SiGN-BN HC+Bootstrap | Gene expression study in hepatocellular carcinoma |
| GSE16987_top500tf - GSE16987 - SiGN-BN HC+Bootstrap | A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis |
| GSE17536_top500tf - GSE17536 - SiGN-BN HC+Bootstrap | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (Moffitt Samples) |
| GSE17705_top500tf - GSE17705 - SiGN-BN HC+Bootstrap | Endocrine Sensitivity Index Validation Dataset |
| GSE17764_top500tf - GSE17764 - SiGN-BN HC+Bootstrap | Expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients |
| GSE17920_top500tf - GSE17920 - SiGN-BN HC+Bootstrap | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
| GSE18088_top500tf - GSE18088 - SiGN-BN HC+Bootstrap | Correlation of molecular profiles and clinical outcome of stage UICC II colon cancer patients |
| GSE18105_top500tf - GSE18105 - SiGN-BN HC+Bootstrap | Stage II and stage III colorectal cancer |
| GSE18497_top500tf - GSE18497 - SiGN-BN HC+Bootstrap | Diagnosis-relapse in ALL |
| GSE19274_top500tf - GSE19274 - SiGN-BN HC+Bootstrap | Expression profiling in Neuroblastoma Primary tumors and Cell lines |
| GSE19494_top500tf - GSE19494 - SiGN-BN HC+Bootstrap | Subcutaneous adipose tissue (SAT) gene expression patterns between weight control and regaining weight subjects |
| GSE19784_top500tf - GSE19784 - SiGN-BN HC+Bootstrap | Gene expression profiling of multiple myeloma patients included in the HOVON65/GMMG-HD4 trial |
| GSE20181_top500tf - GSE20181 - SiGN-BN HC+Bootstrap | Letrozole (Femara) early and late responses to treatment |
| GSE20194_top500tf - GSE20194 - SiGN-BN HC+Bootstrap | MAQC-II Project: human breast cancer (BR) data set |
| GSE2034_top500tf - GSE2034 - SiGN-BN HC+Bootstrap | Breast cancer relapse free survival |
| GSE20842_top500tf - GSE20842 - SiGN-BN HC+Bootstrap | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE2113_top500tf - GSE2113 - SiGN-BN HC+Bootstrap | Plasma cell dyscrasias expression profiles associated with distinct IGH translocations in multiple myeloma |
| GSE21510_top500tf - GSE21510 - SiGN-BN HC+Bootstrap | Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer |
| GSE22093_top500tf - GSE22093 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients |
| GSE22541_top500tf - GSE22541 - SiGN-BN HC+Bootstrap | Expression data from pulmonary metastases and primary tumors of clear-cell renal cell carcinoma (ccRCC) with different disease-free survivals |
| GSE22597_top500tf - GSE22597 - SiGN-BN HC+Bootstrap | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE2294_top500tf - GSE2294 - SiGN-BN HC+Bootstrap | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23036_top500tf - GSE23036 - SiGN-BN HC+Bootstrap | Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma |
| GSE23120_top500tf - GSE23120 - SiGN-BN HC+Bootstrap | Basal gene expression data from Human Variation Panel |
| GSE23177_top500tf - GSE23177 - SiGN-BN HC+Bootstrap | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23553_top500tf - GSE23553 - SiGN-BN HC+Bootstrap | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23772_top500tf - GSE23772 - SiGN-BN HC+Bootstrap | Why does HAMLET preferentially kill tumor cells? p38-dependent death in tumor but up-regulation of innate immunity in healthy, differentiated cells |
| GSE23806_top500tf - GSE23806 - SiGN-BN HC+Bootstrap | Expression data of glioblastoma stem-like (GS) cell lines, conventional glioma cell lines and primary tumors |
| GSE23988_top500tf - GSE23988 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE23991_top500tf - GSE23991 - SiGN-BN HC+Bootstrap | Effect of zebularine on primary human liver cancer cell lines |
| GSE24124_top500tf - GSE24124 - SiGN-BN HC+Bootstrap | Major gene partners of a favorable biomarker in ER(+) breast cancer |
| GSE24185_top500tf - GSE24185 - SiGN-BN HC+Bootstrap | Gene transcription signature of obesity in breast cancer |
| GSE25055_top500tf - GSE25055 - SiGN-BN HC+Bootstrap | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top500tf - GSE25065 - SiGN-BN HC+Bootstrap | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top500tf - GSE25066 - SiGN-BN HC+Bootstrap | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25428_top500tf - GSE25428 - SiGN-BN HC+Bootstrap | Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor |
| GSE2549_top500tf - GSE2549 - SiGN-BN HC+Bootstrap | Malignant pleural mesothelioma |
| GSE2603_top500tf - GSE2603 - SiGN-BN HC+Bootstrap | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26599_top500tf - GSE26599 - SiGN-BN HC+Bootstrap | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE26906_top500tf - GSE26906 - SiGN-BN HC+Bootstrap | APC colon stage II |
| GSE27480_top500tf - GSE27480 - SiGN-BN HC+Bootstrap | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE2841_top500tf - GSE2841 - SiGN-BN HC+Bootstrap | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE28821_top500tf - GSE28821 - SiGN-BN HC+Bootstrap | Laser-capture microdissected invasive micropapillary carcinomas of the breast |
| GSE2912_top500tf - GSE2912 - SiGN-BN HC+Bootstrap | Molecular classification of multiple myeloma |
| GSE29288_top500tf - GSE29288 - SiGN-BN HC+Bootstrap | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Agilent WG platform) |
| GSE29817_top500tf - GSE29817 - SiGN-BN HC+Bootstrap | Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor (EGFR) Predicts Outcome after Chemoradiotherapy of Lymph Node Negative Cervical Cancer |
| GSE30375_top500tf - GSE30375 - SiGN-BN HC+Bootstrap | Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples |
| GSE30784_top500tf - GSE30784 - SiGN-BN HC+Bootstrap | Gene expression profiling of oral squamous cell carcinoma (OSCC) |
| GSE31279_top500tf - GSE31279 - SiGN-BN HC+Bootstrap | Decoding differentially regulated epithelial and stromal pathways in colorectal cancer |
| GSE32269_top500tf - GSE32269 - SiGN-BN HC+Bootstrap | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE32474_top500tf - GSE32474 - SiGN-BN HC+Bootstrap | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Affymetrix U133 Plus 2.0) |
| GSE3726_top500tf - GSE3726 - SiGN-BN HC+Bootstrap | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4115_top500tf - GSE4115 - SiGN-BN HC+Bootstrap | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
| GSE4122_top500tf - GSE4122 - SiGN-BN HC+Bootstrap | Gene Expression Analysis of Ovarian Samples |
| GSE4459_top500tf - GSE4459 - SiGN-BN HC+Bootstrap | Gene expression signature and the prediction of lymph node metastases |
| GSE4554_top500tf - GSE4554 - SiGN-BN HC+Bootstrap | Gene expression signature of colorectal cancer with microsatellite instability. |
| GSE4573_top500tf - GSE4573 - SiGN-BN HC+Bootstrap | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE4823_top500tf - GSE4823 - SiGN-BN HC+Bootstrap | Comparison of normal breast epithelium and stroma from reduction and I.D.C. cases |
| GSE5206_top500tf - GSE5206 - SiGN-BN HC+Bootstrap | Large-scale deployment of embryonic gene programming in human and murine colon cancer: a new target for intervention. |
| GSE5327_top500tf - GSE5327 - SiGN-BN HC+Bootstrap | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5364_top500tf - GSE5364 - SiGN-BN HC+Bootstrap | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5462_top500tf - GSE5462 - SiGN-BN HC+Bootstrap | Letrozole (Femara) early response to treatment |
| GSE5846_top500tf - GSE5846 - SiGN-BN HC+Bootstrap | NCI-60 Cancer Cell Line |
| GSE5851_top500tf - GSE5851 - SiGN-BN HC+Bootstrap | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE6008_top500tf - GSE6008 - SiGN-BN HC+Bootstrap | Human ovarian tumors and normal ovaries |
| GSE6365_top500tf - GSE6365 - SiGN-BN HC+Bootstrap | Distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| GSE6401_top500tf - GSE6401 - SiGN-BN HC+Bootstrap | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6477_top500tf - GSE6477 - SiGN-BN HC+Bootstrap | Expression data from different stages of plasma cell neoplasm |
| GSE7208_top500tf - GSE7208 - SiGN-BN HC+Bootstrap | Expression data from 59 human colon tumor tissue samples |
| GSE7670_top500tf - GSE7670 - SiGN-BN HC+Bootstrap | Expression data from Lung cancer |
| GSE7696_top500tf - GSE7696 - SiGN-BN HC+Bootstrap | Glioblastoma from a homogenous cohort of patients treated within clinical trial |
| GSE8057_top500tf - GSE8057 - SiGN-BN HC+Bootstrap | Expression data from ovarian cancer cells with time-course and concentration-profiles |
| GSE8332_top500tf - GSE8332 - SiGN-BN HC+Bootstrap | Death receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL |
| GSE8401_top500tf - GSE8401 - SiGN-BN HC+Bootstrap | Gene Signature for Aggression of Melanoma Metastases - Melanoma Metastasis |
| GSE8481_top500tf - GSE8481 - SiGN-BN HC+Bootstrap | Various human cell types |
| GSE8546_top500tf - GSE8546 - SiGN-BN HC+Bootstrap | Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure |
| GSE8835_top500tf - GSE8835 - SiGN-BN HC+Bootstrap | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE9348_top500tf - GSE9348 - SiGN-BN HC+Bootstrap | Expression data from healthy controls and early stage CRC patient's tumor |
| GSE9992_top500tf - GSE9992 - SiGN-BN HC+Bootstrap | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
| GSE9195_top500tf - GSE9195 - SiGN-BN HC+Bootstrap | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
| GSE9309_top500tf - GSE9309 - SiGN-BN HC+Bootstrap | Recovery of biological information under heterogeneous experimental conditions using subgroup standardization. |
| GSE9750_top500tf - GSE9750 - SiGN-BN HC+Bootstrap | Identification of gene expression profiles in cervical cancer |
| GSE9936_top500tf - GSE9936 - SiGN-BN HC+Bootstrap | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
(206 networks)
